A peer-reviewed study published in Reproductive BioMedicine Online demonstrates 96% agreement between Mira at-home LH measurements and transvaginal ultrasound, marking a major milestone in decentralized reproductive care.

SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ — A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech.

The prospective 18-month, STARD-compliant diagnostic accuracy study evaluated the Mira at-home hormone monitor across 121 ovulatory cycles and 890 transvaginal ultrasound scans, comparing quantitative urine testing against the clinical gold standards of ultrasound-confirmed ovulation and serum blood draws. Results showed that ovulation occurred within ±1 day of the Mira luteinizing hormone (LH) peak in 96% of ovulatory cycles (R² = 0.96, P < 0.001).

This research updates 25-year-old industry benchmarks by offering the first STARD-compliant, blinded ultrasound validation of a quantitative four-hormone monitor (measuring LH, E₁3G/estrogen, PDG/progesterone, and FSH).

Key Study Findings & Clinical Data Highlights

• 96% Precision with Ultrasound Gold Standard: The day of ovulation confirmed by serial transvaginal ultrasound aligned within ±1 day of the LH peak measured by the Mira monitor in 96% of cycles, with an intraclass correlation coefficient of 0.971.
• Strong Correlation with Blood Serum Levels: First-morning urine hormone profiles closely mirrored serum blood draws collected within 90 minutes, including LH (R² = 0.92), progesterone metabolite PDG (R² = 0.75), estrogen metabolite E₁3G (R² = 0.73), and FSH (R² = 0.61).
• Biological Variability Beyond Calendar Estimates: Even among women with regular periods, 11% of cycles were anovulatory. Additionally, 12.4% of ovulations occurred while LH levels were still rising, underscoring why tracking continuous multi-hormone patterns offers clearer visibility than single-day binary LH tests or date-based app algorithms.
• Earlier Fertile Window Identification: Urinary estrogen (E₁3G) signals rose approximately 5 to 6 days prior to ovulation, capturing real ovarian follicle development to identify the fertile window earlier than LH tracking alone.

Executive & Expert Commentary

Dr. Thomas P. Bouchard, MD, Lead Author and Clinical Researcher:

“For over two decades, at-home fertility tracking was based on qualitative indicators without providing quantitative hormone values. By evaluating quantitative four-hormone tracking against 890 ultrasound scans with a blinded, STARD-compliant ultrasound protocol, this study establishes rigorous clinical and research benchmarks for at-home ovulation prediction and confirmation.”

Sylvia Kang, Founder and Chief Executive Officer of Mira:

“Women deserve precise biological data about their reproductive health without needing constant clinic visits and serial blood draws. This study validates that quantitative at-home testing delivers clinic-grade hormonal visibility, marking a transformative step forward for decentralized healthcare, fertility care, and personalized hormone monitoring.”

Transforming Reproductive Healthcare & Decentralized Medicine

Traditional fertility monitoring often requires repeated clinic visits for serial serum blood draws and invasive follicular ultrasounds. The study authors concluded that validated, quantitative at-home urine hormone tracking supports broader clinical adoption, offering a reliable, non-invasive diagnostic tool that can reduce reliance on routine clinic visits while improving patient convenience and health literacy.

About Mira

Mira is an innovative women’s health company providing the most advanced at-home hormone testing and tracking technology. By measuring exact numerical hormone concentrations, Mira empowers women with highly accurate, clinically-validated* data to navigate fertility, menopause, and overall hormonal health with confidence. Learn more at shop.miracare.com and join the conversation on TikTok, Instagram, and Facebook.

Media Contact
Mira@Brilliant-Agency.com 

Study Citation: Bouchard et al., Reproductive BioMedicine Online (2026). DOI: 10.1016/j.rbmo.2026.105881

View original content to download multimedia:https://www.prnewswire.com/news-releases/landmark-2026-clinical-study-validates-at-home-quantitative-multi-hormone-monitoring-against-ultrasound-gold-standard-302865867.html

SOURCE Mira